Jelena Kunovac, MD, MS, discusses last week's approval of Cobenfy, an agent with a novel mechanism of action that could revolutionize schizophrenia treatment.
Jelena Kunovac, MD, MS
Advertisement
Dr Kunovac is the co-founder and chief executive officer Redbird Research, Las Vegas, Nevada, and adjunct assistant professor in the Department of Psychiatry at the University of Nevada, Las Vegas.
Articles by Jelena Kunovac, MD, MS
Advertisement
Latest Updated Articles
Advertisement
Advertisement
